Joseph Ojile, MD
Pulmonary Disease · Saint Louis, MONPI 1003895236
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Fisher & Paykel Healthcare Limited at 40.1% of the total. Reporting peaked in 2023 at $126,531 and has fallen 50.5% since, to $62,608 in 2025. Among pulmonary disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,010 payments — averaging $532.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fisher & Paykel Healthcare Limited$216K
- GSK$101K
- Jazz Pharmaceuticals Inc.$39K
- AstraZeneca$33K
- Axsome Therapeutics, Inc.$32K
- Idorsia Pharmaceuticals US Inc$32K
- plus $85K from 36 others
Across 188 payments — averaging $10,248 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$1.2M
- Takeda Pharmaceuticals U.S.A., Inc.$237K
- Somnomed Inc.$194K
- Jazz Pharmaceuticals Inc.$106K
- GE HealthCare$65K
- Harmony Biosciences LLC$43K
- plus $106K from 9 others
What the payments were for
- Consulting fees$294,53355%
- Speaking & faculty fees$208,59039%
- Travel & lodging$15,6703%
- Food & beverage$18,6893%
- Education$3700%
- Gifts$1410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$149,036
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$67,861
- SUNOSI$66,623
- TRELEGY ELLIPTA$46,337
- QUVIVIQ$31,180
- AIR 11$25,902
- Wakix$20,035
- AREXVY$19,993
- BREZTRI$19,790
- ANORO$10,800
- BREZTRI AEROSPHERE$10,742
- Dayvigo$8,513
- ZEPBOUND$8,050
- ANORO ELLIPTA$6,701
- SleepUndivided$1,100
- TEZSPIRE$152
- SYMBICORT$152
- XYWAV$127
- FASENRA$112
- Inspire$105
How this compares
$537,994 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 638 | $476,112 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $146,121 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $112,003 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $90,096 |
| Breo ElliptaFluticasone/Vilanterol | 156 | $76,197 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $39,380 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $24,552 |
| Ambrisentan | 13 | $20,764 |
| Arnuity ElliptaFluticasone Furoate | 63 | $18,115 |
| NuvigilArmodafinil | 13 | $13,986 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 488 | $12,410 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 22 | $10,796 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $10,430 |
| Spiriva HandihalerTiotropium Bromide | 13 | $9,999 |
| Spiriva RespimatTiotropium Bromide | 14 | $9,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $101,351 | $609,805935 claims |
| Grifols USA, LLCProlastin C | $423 | $146,12113 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $32,622 | $125,662179 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $11,860 | $90,09617 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat | $1,224 | $33,62045 claims |
| PfizerEliquis | $14 | $5,02715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
- Shiraz DaudSaint Louis$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.